Update on dengue: Epidemiology, virus evolution, antiviral drugs, and vaccine development

被引：152

作者：

Wilder-Smith A. ^{[1
,2
]}

Ooi E.-E. ^{[2
]}

Vasudevan S.G. ^{[2
]}

Gubler D.J. ^{[2
]}

机构：

[1] Department of Medicine, National University of Singapore, Singapore 119074

[2] Emerging Infectious Diseases Program, Duke-NUS, Singapore

来源：

Current Infectious Disease Reports | 2010年 / 12卷 / 3期

关键词：

Dengue; Dengue antiviral compounds; Dengue antiviral therapy; Dengue genotypes; Dengue serotypes; Dengue vaccines; Epidemiology of dengue; Expansion of dengue;

D O I：

10.1007/s11908-010-0102-7

中图分类号：

学科分类号：

摘要：

Dengue virus is the most widespread geographically of the arboviruses and a major public health threat in the tropics and subtropics. Scientific advances in recent years have provided new insights about the pathogenesis of more severe disease and novel approaches into the development of antiviral compounds and dengue vaccines. Phylogenetic studies show an association between specific subtypes (within serotypes) and severity of dengue. The lack of association between maternal antibodies and development of severe dengue in infants in a recent study has called for the rethinking or refinement of the current antibody-dependent enhancement theory of dengue hemorrhagic syndrome in infancy. Such studies should stimulate new directions of research into mechanisms responsible for the development of severe dengue. The life cycle of dengue virus readily shows that virus entry and replication can be targeted by small molecules. Advances in a mouse model (AG 129 mice) have made it easier to test such antiviral compounds. The efforts to find specific dengue inhibitors are intensifying and the tools to evaluate the efficacy of new drugs are now in place for rapid translation into trials in humans. Furthermore, several dengue vaccine candidates are in development, of which the chimeric dengue/yellow fever vaccine has now entered phase 3 trials. Until the availability of a licensed vaccine, disease surveillance and vector population control remain the mainstay of dengue prevention. © Springer Science+Business Media LLC 2010.

引用

页码：157 / 164

页数：7

共 61 条

[1]

Gubler D.J., The global emergence/resurgence of arboviral diseases as public health problems, Arch Med Res, 33, pp. 330-342, (2002)

[2]

Halstead S.B., Dengue virus-mosquito interactions, Annu Rev Entomol, 53, pp. 273-291, (2008)

[3]

Effler P.V., Pang L., Kitsutani P., Vorndam V., Nakata M., Ayers T., Elm J., Tom T., Reiter P., Rigau-Perez J.G., Hayes J.M., Mills K., Napier M., Clark G.G., Gubler D.J., Dengue fever, Hawaii, 2001-2002, Emerging Infectious Diseases, 11, 5, pp. 742-749, (2005)

[4]

Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control, (2009)

[5]

Suaya J.A., Shepard D.S., Siqueira J.B., Et al., Cost of dengue cases in eight countries in the Americas and Asia: A prospective study, Am J Trop Med Hyg, 80, pp. 846-855, (2009)

[6]

Halstead S.B., Udomsakdi S., Simasthien P., Et al., Observations related to pathogenesis of dengue hemorrhagic fever. I. Experience with classification of dengue viruses, Yale J Biol Med, 42, pp. 261-275, (1970)

[7]

Wilder-Smith A., Gubler D.J., Geographic expansion of dengue: The impact of international travel, Med Clin North Am, 92, pp. 1377-1390, (2008)

[8]

Ooi E., Gubler D.J., Global spread of epidemic dengue: The influence of environmental change, Future Virol, 4, pp. 571-580, (2009)

[9]

Cheng S., Kalkstein L.S., Focks D.A., Nnaji A., New Procedures to Estimate Water Temperatures and Water Depths for Application in Climate-Dengue Modeling, Journal of Medical Entomology, 35, 5, pp. 646-652, (1998)

[10]

Egger J.R., Eng E.O., Kelly D.W., Woolhouse M.E., Daviesa C.R., Colemana P.G., Reconstructing historical changes in the force of infection of dengue fever in Singapore: Implications for surveillance and control, Bulletin of the World Health Organization, 86, 3, pp. 187-196, (2008)

← 1 2 3 4 5 6 7 →